ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 700,75
0,50%
Dow Jones
39 112,16
-0,76%
DAX
18 341,60
0,99%
Brent Oil
84,465
0,33%
Bitcoin
61 488,66
-0,52%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. AC Immune SA (ACIU)

  7. AC Immune SA (ACIU) Actualités

ACIU

AC Immune (ACIU)

AC Immune SA
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ACIU
DateHeureSourceTitreSymboleSociété
21/05/202414h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ACIUAC Immune SA
16/05/202420h23Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ACIUAC Immune SA
09/02/202422h30Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ACIUAC Immune SA
03/01/202414h10GlobeNewswire Inc.AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseasesNASDAQ:ACIUAC Immune SA
15/12/202323h27Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ACIUAC Immune SA
27/06/202319h30AllPennyStocks.comBiotech Pops On FDA Fast Track DesignationNASDAQ:ACIUAC Immune SA
27/06/202314h23Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:ACIUAC Immune SA
27/06/202314h11Dow Jones NewsAC Immunity Shares Jump 18% After Fast-Track Designation on Alzheimer's TreatmentNASDAQ:ACIUAC Immune SA
16/03/202312h32Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:ACIUAC Immune SA
10/02/202322h02Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ACIUAC Immune SA
01/12/202214h45TipRanksH.C. Wainwright Keeps Their Buy Rating on AC Immune SA (ACIU)NASDAQ:ACIUAC Immune SA
02/11/202205h45TipRanksSVB Securities Sticks to Its Buy Rating for AC Immune SA (ACIU)NASDAQ:ACIUAC Immune SA
31/10/202211h15TipRanksAC Immune SA (ACIU) Receives a Buy from H.C. WainwrightNASDAQ:ACIUAC Immune SA
29/08/202205h15TipRanksSVB Securities Keeps Their Buy Rating on AC Immune SA (ACIU)NASDAQ:ACIUAC Immune SA
11/07/202214h40TipRanksSVB Securities Thinks AC Immune SA’s Stock is Going to RecoverNASDAQ:ACIUAC Immune SA
19/06/202209h05TipRanksH.C. Wainwright Sticks to Their Buy Rating for AC Immune SA (ACIU)NASDAQ:ACIUAC Immune SA
16/06/202212h57Dow Jones NewsAC Immune Shares Fall Premarket on Alzheimer's Study MissNASDAQ:ACIUAC Immune SA
29/04/202212h26TipRanksH.C. Wainwright Thinks AC Immune SA’s Stock is Going to RecoverNASDAQ:ACIUAC Immune SA
21/12/202108h11TipRanksLeerink Partners Sticks to Its Buy Rating for AC Immune SA (ACIU)NASDAQ:ACIUAC Immune SA
12/11/202115h44Dow Jones NewsAC Immune Sees Positive Data in Trial for Alzheimer's Disease TreatmentNASDAQ:ACIUAC Immune SA
31/08/202116h55Dow Jones NewsAC Immune Shares Rally on Renewed Hope for Semorinemab in Alzheimer'sNASDAQ:ACIUAC Immune SA
31/08/202114h33Dow Jones NewsAC Immune: Semorinemab Meets Co-Primary Endpoint in Alzheimer's DiseaseNASDAQ:ACIUAC Immune SA
05/08/202123h16Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:ACIUAC Immune SA
27/07/202114h00GlobeNewswire Inc.AC Immune acquires AFFiRiS’ Specific Active Immunotherapy (SAIT) anti-alpha-synuclein programs targeting neurodegenerative diseasesNASDAQ:ACIUAC Immune SA
06/05/202112h07Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:ACIUAC Immune SA
23/11/202022h31Edgar (US Regulatory)Amended Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k/a)NASDAQ:ACIUAC Immune SA
23/10/202023h24Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-3)NASDAQ:ACIUAC Immune SA
23/09/202019h30Dow Jones NewsAC Immune Down 43%; Semorinemab Didn't Meet Endpoint in Early Alzheimer's DiseaseNASDAQ:ACIUAC Immune SA
23/09/202015h23Dow Jones NewsAC Immune Down; Semorinemab Didn't Meet Efficacy Endpoint in Early Alzheimer's DiseaseNASDAQ:ACIUAC Immune SA
23/09/202013h59Dow Jones NewsAC Immune: Semorinemab Didn't Meet Co-Primary Efficacy Endpoint in Early Alzheimer's DiseaseNASDAQ:ACIUAC Immune SA
 Showing the most relevant articles for your search:NASDAQ:ACIU

Dernières Valeurs Consultées

NYSE
JPM
JP Morgan Chase
EU
LR
Legrand
NASDAQ
NVDA
NVIDIA
EU
MC
Lvmh Moet Hennessy Louis...
EU
AF
Air FranceKLM
FTSE
UKX
FTSE 100
COIN
BTCUSD
Bitcoin
USI
USTECH100
US Tech 100
EU
SGO
Cie de SaintGobain
EU
HO
Thales
NASDAQ
AMZN
Amazon.com
EU
BN
Danone
NASDAQ
AAPL
Apple
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés